Salix Pharmaceuticals, Ltd.

Shareholder Corporation Litigation

Rigrodsky & Long, P.A. Announces Investigation Of Salix Pharmaceuticals, Inc. (NASDAQ GS: SLXP) Buyout

Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Salix Pharmaceuticals, Ltd. (“Salix” or the “Company”) (NASDAQ GS: SLXP) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE: VRX), in a transaction valued at approximately $14.5 billion.

Under the terms of the agreement, public shareholders of Salix would receive $158.00 in cash for each share of Salix they own.

The investigation concerns whether Salix’s board of directors failed to adequately shop the Company and obtain the best possible value for Salix’s shareholders before entering into an agreement with Valeant.  According to Yahoo! Finance, at least one analyst has issued a price target for Salix stock at $185.00 per share.

If you own the common stock of Salix and purchased your shares before February 23, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail to

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.